ERRATUM
https://doi.org/10.29289/2594539420220036ERRATUM

In the manuscript "Axillary surgical approach in T1-T2N0M0 clinical breast cancer staging: Survival in a women's hospital cohort in Rio de Janeiro", DOI: 10.29289/2594539420220036, published in the Mastology 2022;32:e20220036, on pages 4-5:

Where it reads:

Table 1. Distribution of sociodemographic and clinicopathologic status and treatment characteristics, according to axillary approach of the cohort of 827 women with breast cancer, treated at the Brazilian National Cancer Institute (2007–2009).

	Total*	Axillary surgery n(%)		χ^2
	n (%)	SLNB	SLNB+AL[a]	p-value
Age				
<40	54 (6.5)	41 (6.0)	13 (9.0)	0.049
40–59	426 (51.5)	343 (50.2)	83 (57.6)	
≥60	347 (42.0)	299 (43.8)	48 (33.3)	
Skin color				
Non-White	267 (32.3)	229 (33.5)	38 (26.4)	0.096
White	560 (67.7)	454 (66.5)	106 (73.6)	
Marital status				
With a partner	431 (52.1)	346 (50.7)	85 (59.0)	0.068
No partner	396 (47.9)	337 (49.3)	59 (41.0)	
Schooling				
<8 years	350 (42.4)	296 (43.3)	54 (37.8)	0.220
≥8 years	476 (57.6)	387 (56.7)	89(62.2)	
Occupation				
Unemployed	32 (3.9)	28 (4.1)	4 (2.8)	0.482
External job	372 (45.3)	301 (44.5)	71 (49.3)	
At home	417 (50.8)	348 (51.4)	69 (47.9)	
Alcoholism				
No	597 (73.0)	487 (72.1)	110 (76.9)	0.243
Yes	221 (27.0)	188 (27.9)	33 (23.1)	
Smoking				
No	562 (68.2)	467 (68.6)	95 (66.4)	0.617
Yes	262 (31.8)	214 (31.4)	48 (33.6)	
BMI				
Low weight	35 (4.2)	30 (4.4)	5 (3.5)	0.583
Suitable weight	227 (27.4)	193 (28.3)	34 (23.6)	
Overweight	297 (35.9)	244 (35.7)	53 (36.8)	
Obesity	268 (32.4)	216 (31.6)	52 (36.1)	
Clinical staging				
T1N0M0 (I)	543 (65.7)	478 (70.0)	65 (45.1)	0.000
T2N0M0 (IIA)	284 (34.3)	205 (30.0)	79 (54.9)	
Tumor size				
T1	566 (68.5)	495 (72.6)	71 (49.3)	0.000
T2	253 (30.6)	184 (27.0)	69 (47.9)	
T3	7 (0.8)	3 (0.4)	4 (2.8)	
Histological type				
Lobular Invasive	52 (6.3)	40 (5.9)	12 (8.3)	0.249
Ductal Invasive	713 (86.2)	588 (86.1)	125 (86.8)	
Others	62 (7.5)	55 (8.1)	7 (4.9)	
Histological grade				
1	166 (22.7)	145 (24.2)	21 (16.0)	0.038
2	293 (40.1)	243 (40.6)	50 (38.2)	
3	271 (37.1)	211 (35.2)	60 (45.8)	
Number of lymph nodes removed				
1–3	619 (74.8)	619 (90.6)	0 (0.0)	0.000
4–10	72 (8.7)	64 (9.4)	8 (5.6)	
>10	136(16.4)	0 (0.0)	136 (94.4)	
Lymph node status				
No metastasis				
With metastasis				

Continue...

Table 1. Continuation.

	Total*	Axillary surgery n(%)		χ^2
	n (%)	SLNB	SLNB+AL[a]	p-value
Sentinel lymph node metastasis				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
Micrometastasis	41 (5.0)	17 (2.5)	24 (16.7)	
Macrometastasis	87 (10.5)	0 (0.0)	87 (60.4)	
Status HER2[b]				
Negative	368 (74.8)	295 (75.4)	73 (72.3)	0.366
Positive	70 (14.2)	57 (14.6)	13 (12.9)	
Indeterminate	54 (11.0)	39 (10.0)	15 (14.9)	
Hormonal receptor				
Positive	694 (84.7)	564 (83.6)	130 (90.3)	0.042
Negative	125 (15.3)	111 (16.4)	14 (9.7)	
Triple negative[b]				
No	436 (90.8)	343 (89.8)	93 (94.9)	0.118
Yes	44 (9.2)	39 (10.2)	5 (5.1)	
Other primary cancer				
No	812 (98.2)	672 (98.4)	140 (97.2)	0.340
Yes	15 (1.8)	11 (1.6)	4 (2.8)	
Death				
No	794 (96.0)	659 (96.5)	135 (93.8)	0.127
Yes	33 (4.0)	24 (3.5)	9 (6.2)	
Lymph node status				
No metastasis	699 (84,5)	666 (97,5)	33 (22,9)	0,000
With metastasis	128(15,5)	17 (2,5)	111 (77,1)	
Locoregional recurrence				
No	808 (97.7)	665 (97.4)	143 (99.3)	0.158
Yes	19 (2.3)	18 (2.6)	1 (0.7)	
Distance recurrence				
No	790 (95.5)	657 (96.2)	133 (92.4)	0.043
Yes	37 (4.5)	26 (3.8)	11 (7.6)	
Breast surgery				
Conservative	484 (58.5)	423 (61.9)	61 (42.4)	0.000
Mastectomy	343 (41.5)	260 (38.1)	83 (57.6)	
Breast reconstruction				
No	681 (82.3)	557 (81.6)	124 (86.1)	0.192
Yes	146 (17.7)	126 (18.4)	20 (13.9)	
Chemotherapy				
No	409 (49.5)	381 (55.8)	28 (19.4)	0.000
Yes	418 (50.5)	302 (44.2)	116 (80.6)	
Radiotherapy				
No	328 (39.7)	265 (38.8)	63 (43.8)	0.270
Yes	499 (60.3)	418 (61.2)	81 (56.2)	
Hormonal therapy				
No	169 (20.4)	150 (22.0)	19 (13.2)	0.018
Yes	658 (79.6)	533 (78.0)	125 (86.8)	
Target therapy				
No	790 (95.5)	655 (95.9)	135 (93.8)	0.257
Yes	37 (4.5)	28 (4.1)	9 (6.2)	
Severity score[c]				
0–1	78 (9.4)	78 (11.4)	0 (0.0)	0.000
2–4	675 (81.6)	573 (83.9)	102 (70.8)	
5–6	74 (8.9)	32 (4.7)	42 (29.2)	

SLNB: sentinel lymph node biopsy; AL: axillary lymphadenectomy; BMI: body mass index; HER2: human epidermal growth factor receptor 2; χ^2: Pearson's χ^2 test; Non-white: black, brown. *The total value may change due to missing values. [a]Sentinel lymph node biopsy with a subsequent axillary lymphadenectomy. [b]The analysis of molecular markers has become routine at Brazilian National Cancer Institute starting 2011, not all patients underwent the tests. [c]Severity score includes age, clinical staging, histological grade, and lymph node status.

It should read:

Table 1. Distribution of sociodemographic and clinicopathologic status and treatment characteristics, according to axillary approach of the cohort of 827 women with breast cancer, treated at the Brazilian National Cancer Institute (2007–2009).

	Total*	Axillary surgery N(%)		x^2
	n (%)	SLNB	SLNB+AL[a]	p-value
Age				
<40	54 (6.5)	41 (6.0)	13 (9.0)	0.049
40–59	426 (51.5)	343 (50.2)	83 (57.6)	
≥60	347 (42.0)	299 (43.8)	48 (33.3)	
Skin color				
Non-White	267 (32.3)	229 (33.5)	38 (26.4)	0.096
White	560 (67.7)	454 (66.5)	106 (73.6)	
Marital status				
With a partner	431 (52.1)	346 (50.7)	85 (59.0)	0.068
No partner	396 (47.9)	337 (49.3)	59 (41.0)	
Schooling				
<8 years	350 (42.4)	296 (43.3)	54 (37.8)	0.220
≥8 years	476 (57.6)	387 (56.7)	89(62.2)	
Occupation				
Unemployed	32 (3.9)	28 (4.1)	4 (2.8)	0.482
External job	372 (45.3)	301 (44.5)	71 (49.3)	
At home	417 (50.8)	348 (51.4)	69 (47.9)	
Alcoholism				
No	597 (73.0)	487 (72.1)	110 (76.9)	0.243
Yes	221 (27.0)	188 (27.9)	33 (23.1)	
Smoking				
No	562 (68.2)	467 (68.6)	95 (66.4)	0.617
Yes	262 (31.8)	214 (31.4)	48 (33.6)	
BMI				
Low weight	35 (4.2)	30 (4.4)	5 (3.5)	0.583
Suitable weight	227 (27.4)	193 (28.3)	34 (23.6)	
Overweight	297 (35.9)	244 (35.7)	53 (36.8)	
Obesity	268 (32.4)	216 (31.6)	52 (36.1)	
Clinical staging				
T1N0M0 (I)	543 (65.7)	478 (70.0)	65 (45.1)	0.000
T2N0M0 (IIA)	284 (34.3)	205 (30.0)	79 (54.9)	
Tumor size				
T1	566 (68.5)	495 (72.6)	71 (49.3)	0.000
T2	253 (30.6)	184 (27.0)	69 (47.9)	
T3	7 (0.8)	3 (0.4)	4 (2.8)	
Histological type				
Lobular Invasive	52 (6.3)	40 (5.9)	12 (8.3)	0.249
Ductal Invasive	713 (86.2)	588 (86.1)	125 (86.8)	
Others	62 (7.5)	55 (8.1)	7 (4.9)	
Histological grade				
1	166 (22.7)	145 (24.2)	21 (16.0)	0.038
2	293 (40.1)	243 (40.6)	50 (38.2)	
3	271 (37.1)	211 (35.2)	60 (45.8)	
Number of lymph nodes removed				
1–3	619 (74.8)	619 (90.6)	0 (0.0)	0.000
4–10	72 (8.7)	64 (9.4)	8 (5.6)	
>10	136(16.4)	0 (0.0)	136 (94.4)	
Sentinel lymph node metastasis				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
Micrometastasis	41 (5.0)	17 (2.5)	24 (16.7)	
Macrometastasis	87 (10.5)	0 (0.0)	87 (60.4)	

Continue...

Table 1. Continuation.

	Total*	Axillary surgery N(%)		x^2
	n (%)	SLNB	SLNB+AL[a]	p-value
Status HER2[b]				
Negative	368 (74.8)	295 (75.4)	73 (72.3)	0.366
Positive	70 (14.2)	57 (14.6)	13 (12.9)	
Indeterminate	54 (11.0)	39 (10.0)	15 (14.9)	
Hormonal receptor				
Positive	694 (84.7)	564 (83.6)	130 (90.3)	0.042
Negative	125 (15.3)	111 (16.4)	14 (9.7)	
Triple negative[b]				
No	436 (90.8)	343 (89.8)	93 (94.9)	0.118
Yes	44 (9.2)	39 (10.2)	5 (5.1)	
Other primary cancer				
No	812 (98.2)	672 (98.4)	140 (97.2)	0.340
Yes	15 (1.8)	11 (1.6)	4 (2.8)	
Death				
No	794 (96.0)	659 (96.5)	135 (93.8)	0.127
Yes	33 (4.0)	24 (3.5)	9 (6.2)	
Lymph node statu				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
With metastasis	128(15.5)	17 (2.5)	111 (77.1)	
Locoregional recurrence				
No	808 (97.7)	665 (97.4)	143 (99.3)	0.158
Yes	19 (2.3)	18 (2.6)	1 (0.7)	
Distance recurrence				
No	790 (95.5)	657 (96.2)	133 (92.4)	0.043
Yes	37 (4.5)	26 (3.8)	11 (7.6)	
Breast surgery				
Conservative	484 (58.5)	423 (61.9)	61 (42.4)	0.000
Mastectomy	343 (41.5)	260 (38.1)	83 (57.6)	
Breast reconstruction				
No	681 (82.3)	557 (81.6)	124 (86.1)	0.192
Yes	146 (17.7)	126 (18.4)	20 (13.9)	
Chemotherapy				
No	409 (49.5)	381 (55.8)	28 (19.4)	0.000
Yes	418 (50.5)	302 (44.2)	116 (80.6)	
Radiotherapy				
No	328 (39.7)	265 (38.8)	63 (43.8)	0.270
Yes	499 (60.3)	418 (61.2)	81 (56.2)	
Hormonal therapy				
No	169 (20.4)	150 (22.0)	19 (13.2)	0.018
Yes	658 (79.6)	533 (78.0)	125 (86.8)	
Target therapy				
No	790 (95.5)	655 (95.9)	135 (93.8)	0.257
Yes	37 (4.5)	28 (4.1)	9 (6.2)	
Severity score[c]				
0–1	78 (9.4)	78 (11.4)	0 (0.0)	0.000
2–4	675 (81.6)	573 (83.9)	102 (70.8)	
5–6	74 (8.9)	32 (4.7)	42 (29.2)	

SLNB: sentinel lymph node biopsy; AL: axillary lymphadenectomy; BMI: body mass index; HER2: human epidermal growth factor receptor 2; x^2: Pearson's x^2 test; Non-white: black, brown. *The total value may change due to missing values. [a]Sentinel lymph node biopsy with a subsequent axillary lymphadenectomy. [b]The analysis of molecular markers has become routine at Brazilian National Cancer Institute starting 2011, not all patients underwent the tests. [c]Severity score includes age, clinical staging, histological grade, and lymph node status.

This is an open access article distributed under the terms of the Creative Commons license.